Meet HyTest Team at CACLP Expo!

Published: 01.03.2024
01 Mar, 2024
New Monoclonal Anti-Influenza Virus Type B Antibody

Launch of HyTest’s latest monoclonal antibodies targeting the nucleoprotein of influenza B virus!

Read more
01 Mar, 2024
Hope Beyond Trauma: Navigating the Complex World of Brain Injuries

The Brain Injury Association of America (BIAA) designates March as a month to raise awareness about brain injuries.

Read more
01 Mar, 2024
HyTest North America Opening

We are pleased to inform you that Hytest North America, a subsidiary of Hytest Ltd, will launch local operations in March 2024!

Read more
31 Jan, 2024
Empowering Women's Heart Health: Innovations and Insights in Cardiovascular Diagnostics

February is American Heart Month, emphasizing the importance of heart health, with a focus on women this year due to their unique risk and often underdiagnosed heart conditions. Current AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guidelines for the Evaluation and Diagnosis of Acute Chest Pain highlight the gender-specific nature of heart disease diagnosis, particularly noting that women generally have lower baseline levels of troponin.

At HyTest, we are dedicated to meeting this gender-specific diagnostic need through our innovations in cardiac diagnostics, especially in troponins. Our product range includes approximately 50 antibodies targeting various epitopes of the cardiac troponin I (cTnI) molecule, complemented by our advanced cardiac troponin and troponin complex antigens. For more detailed information, please refer to our Cardiac Markers Brochure.

Read more
04 Jan, 2024
Covid-19 Products Update

HyTest antibodies should recognize Pirola and Eris variants.

Read more
19 Dec, 2023
Launching recombinant procollagen type I N-propetide antigen: Advancing Bone Disease Awareness

Procollagen type I N-propetide (PINP) in blood is recommended as a reference marker for bone formation in osteoporosis by the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry (IFCC) bone marker standards joint working group. PINP, in particular, has emerged as a recommended reference marker for bone formation in osteoporosis, aiding in monitoring antiresorptive and anabolic therapies.

Read more
30 Nov, 2023
Call for Nominations: IFCC Distinguished Award for Contributions to Cardiovascular Diagnostics – Sponsored by HyTest

This distinguished award seeks to recognize and honours outstanding individuals who have made significant contributions to the field of Cardiovascular Diagnostics.

Read more
30 Nov, 2023
Role of HyTest in Cardiac Troponin Detection and Myocardial Infarction Diagnosis

At HyTest, our specialization in cardiac troponin (cTn) detection spans nearly three decades. Over the years, we have generated and analysed thousands of cTn-specific antibodies.

Read more
31 Oct, 2023
New Recombinant Human Cardiac Troponin Complex

We're delighted to announce the launch of our latest troponin product: the recombinant chimeric human Cardiac Troponin binary Complex (Cat. # 8IFC20). This unique complex features the most stable part of cTnI (fragment 28-110) linked with TnC by a 20-aar flexible linker of the cTn I – C complex.

Read more
27 Sep, 2023
Meet us at Medica 2023 in November

We will be attending Medica 2023 in November.

Read more
05 Jul, 2023
Hytest Appoints New CCO and General Manager of Hytest China

We have been privileged to have Soozy and Linda on our team for about 10 years. Now the story continues with new job descriptions – Soozy Xi will continue as CCO of HyTest and Linda Li will take on the role of General Manager of HyTest China. The whole team warmly congratulates! We also got a few comments from them:

Read more
05 Jul, 2023
Hytest Webinar: Clinical Applications of Procalcitonin (PCT) and Challenges in Measurement Standardization

Procalcitonin (PCT) is an established biomarker, which is used to guide antibiotic treatment in septic patient. As an invaluable indicator, it shows high sensitivity and specificity for bacterial infection. Given the utility of PCT in clinical setting, variability in results from different commercial assays have been observed. In this webinar, participants will have the opportunity to review the clinical application of PCT, technology used for PCT measurements and also the challenges in terms of the standardization effort.

Read more
20 Jun, 2023
Meet us at AACC Annual Scientific Meeting & Clinical Lab Expo in July

#teamhytest is looking forward to meeting our customers at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo in Anaheim!

Read more
13 Jun, 2023
Hut Coats Appointed as General Manager of Hytest North America

We are happy to introduce General Manager of HyTest North America Hut Coats. With Hut in our team, we’re able to be closer to our customers in North America and provide even better service.

Read more
01 Jun, 2023
The Winner of the Fourth EFLM-HyTest Cardiac Marker

The EFLM Award Committee had a difficult task in selecting for the most remarkable scientific work among the submitted papers but in the end Rami Aalto, (University of Turku, Finland) was selected to receive the award.

Read more
17 May, 2023
Hytest Appoints Netta Keinänen as New CEO

We are pleased to announce that Netta Keinänen, a valued member of our leadership team, will be stepping into the role of CEO on June 5th, 2023. With her experience, leadership, and strategic vision, we are confident that Netta will continue to lead us to even greater success.  

Read more
27 Apr, 2023
New Troponin Product Available

We have launched a new troponin MAb Y302 recombinant monoclonal antibody, which is expressed in a mammalian cell line and contains full-size IgG sequence derived from rabbit B cells and epitope specificity for this MAb is 83 – 100 a.a.r. of human cardiac troponin I.

Read more
30 Mar, 2023
New Article: Fragmentation of Human Cardiac Troponin T After Acute Myocardial Infarction

A new article titled "Fragmentation of human cardiac troponin T after acute myocardial infarction" by our scientists was published in Clinica Chimica Acta journal.

Read more
30 Mar, 2023
New Product: Recombinant Thyroglobulin

We are launching a new product, recombinant thyroglobulin, Cat # 8RTG4.

Read more

Do you need samples?

We are happy to make you an offer